PSTV
Plus Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
PSTV fundamentals
Plus Therapeutics (PSTV) released its earnings on Aug 14, 2025: revenue was 1.39M (YoY +8.68%), missed estimates; EPS was -0.01 (YoY +98.59%), beat estimates.
Revenue / YoY
1.39M
+8.68%
EPS / YoY
-0.01
+98.59%
Report date
Aug 14, 2025
Earnings Call
4:00 PM on Aug 14, 2025
Meeting link.EPS
Revenue
Revenue & Expenses
PSTV has released its 2025 Q3 earnings report, with revenue of 1.40M, reflecting a YoY change of -4.05%, and net profit of -4.42M, showing a YoY change of -53.90%. The Sankey diagram below clearly presents PSTV's revenue sources and cost distribution.
Key Indicators
Plus Therapeutics (PSTV) key financial stats and ratios, covering profitability, financial health, and leverage.
Plus Therapeutics (PSTV)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Plus Therapeutics (PSTV)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Plus Therapeutics (PSTV)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Plus Therapeutics (PSTV) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Plus Therapeutics (PSTV) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What guidance did Plus Therapeutics's management provide for the next earnings period?What factors drove the changes in Plus Therapeutics's revenue and profit?What were the key takeaways from Plus Therapeutics’s earnings call?What is Plus Therapeutics's gross profit margin?What is the revenue and EPS growth rate for Plus Therapeutics year over year?What does Plus Therapeutics do and what are its main business segments?What is the market's earnings forecast for Plus Therapeutics next quarter?Did Plus Therapeutics beat or miss consensus estimates last quarter?
